 "Dr Reddy's Q1 profit up 1% to ₹1,410 crore, revenue rises to ₹8,545 cr")
Dr Reddy's Laboratories on Wednesday reported a 1 per cent increase in consolidated net profit to ₹1,410 crore during the Juen quarter.
The Hyderabad-based drug major reported a net profit of ₹1,392 crore in the year-ago period.
Revenue increased to ₹8,545 crore in he period under review from ₹7,673 crore a year earlier.
"We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio," Dr Reddy's Co-Chairman & MD G V Prasad said.
The pricing pressure on Lenalidomide is expected to intensify in the US generics market, he noted.
"We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development," Prasad said.
Shares of the company ended 0.58 per cent up at ₹1,247.55 apiece on the BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app